Search

everythinglearnresearchcommunity

for

Search:↓

Both atopy and eosinophilia are linked to more severe hair loss in people with alopecia areata.

There is no significant link between alopecia areata and the PON1 enzyme polymorphisms studied.

The study concluded that patients with total hair loss and recurring hair loss had an earlier onset, longer-lasting condition, and a greater negative impact on their quality of life, with allergic conditions linked to more severe hair loss.

Alopecia areata incognita causes widespread hair loss without patches and needs a scalp biopsy for diagnosis.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Skin grafts on mice can cause an immune response leading to hair loss, useful for studying human hair loss conditions.

Tofacitinib may help treat severe hair loss, but more research is needed.

No single treatment is consistently effective for alopecia areata, and more research is needed.

Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Trichoscopy helps diagnose and monitor alopecia areata by looking at a combination of specific hair and scalp features.

Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.

Minoxidil helps hair regrowth in alopecia patients, with 16 having good results and no side effects.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.